The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
in vitro
and
in vivo
models of multiple myeloma by blockade of Ikaros and MYC signaling
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
in vitro
and
in vivo
models of multiple myeloma by blockade of Ikaros and MYC signaling
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now